Source:

Mahanatx.com

Disclosures: Mayer is on the clinical advisory board at Mahana Therapeutics.
December 11, 2020
1 min read
Save

Mahana obtains marketing authorization for IBS digital therapeutic

Source:

Mahanatx.com

Disclosures: Mayer is on the clinical advisory board at Mahana Therapeutics.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Parallel, a prescription digital therapeutic developed by Mahana Therapeutics for the treatment of irritable bowel syndrome, received marketing authorization from the FDA, according to a company press release.

The 3-month digital program uses cognitive behavioral therapy to help adults change factors that might contribute to IBS.

“Parallel provides adult patients suffering from any subtype of IBS with a clinically validated, digitally delivered, cognitive behavioral therapy-based complementary treatment,” Emeran Mayer, MD, a distinguished professor at UCLA, and member of Mahana’s clinical advisory board, said in the release. “Cognitive behavioral therapy has increasingly been incorporated into gastrointestinal patient care, and this digital model increases access to this important treatment approach. Prescription digital therapeutics, working in ‘parallel’ with medications and other treatments represent an exciting new frontier in medicine.”

The program showed positive results in a randomized controlled trial comprising more than 550 patients with IBS. After 3 months of treatment, patients who used Parallel experienced reductions in severity of IBS symptoms.